Stevanato Group (NYSE:STVN) Issues Quarterly Earnings Results

Stevanato Group (NYSE:STVN) issued its quarterly earnings results on Tuesday. The company reported €0.16 earnings per share for the quarter, missing the consensus estimate of €0.17 by (€0.01), FiscalAI reports. Stevanato Group had a return on equity of 10.43% and a net margin of 10.99%. The business had revenue of €326.10 million for the quarter.

Here are the key takeaways from Stevanato Group’s conference call:

• Third-quarter results were solid: revenue rose 8% organically to €326.1 million, adjusted EBITDA increased 14% to €88.8 million, and the adjusted EBITDA margin expanded 150 basis points to 27.2%.
• Management reiterated full-year 2026 guidance, including revenue of €1.26–€1.28 billion, adjusted EBITDA of €335–€345.2 million, and adjusted diluted EPS of €0.60–€0.62; stronger BDS growth is expected to offset a lower engineering outlook.
• The company expects a temporary moderation in 2027 growth because one GLP-1 customer is reducing Nexa syringe volumes; management now expects low-single-digit growth rather than its longer-term high-single-digit to low-double-digit target, although it says most of the shortfall has been backfilled.
• Non-GLP biologics revenue grew more than 30% in the quarter and 13% year to date, while demand remains strong for Alba syringes, EZ-fill cartridges and vials, and delivery devices; management expects broader biologics and biosimilars demand to support a return to normalized growth beyond 2027.
• Engineering revenue fell 12% as customer orders were delayed, and management acknowledged that order conversion remains below target; the company is also evaluating the segment’s strategic role because its visual inspection and assembly activities are dilutive to corporate margins.

Stevanato Group Price Performance

Shares of STVN stock traded down €5.12 during trading hours on Tuesday, hitting €14.62. The stock had a trading volume of 1,085,888 shares, compared to its average volume of 495,172. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.61 and a quick ratio of 1.08. The stock has a market capitalization of $4.43 billion, a price-to-earnings ratio of 26.15, a PEG ratio of 1.60 and a beta of 0.78. Stevanato Group has a one year low of €12.89 and a one year high of €27.00. The stock’s 50-day moving average price is €20.52 and its two-hundred day moving average price is €18.14.

Analysts Set New Price Targets

A number of brokerages recently commented on STVN. Weiss Ratings raised Stevanato Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, August 27th. UBS Group assumed coverage on Stevanato Group in a report on Wednesday, September 9th. They set a “neutral” rating and a $23.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft started coverage on Stevanato Group in a report on Wednesday, October 7th. They set a “hold” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Stevanato Group presently has an average rating of “Moderate Buy”.

Insider Transactions at Stevanato Group

In other Stevanato Group news, insider Mauro Stocchi sold 13,649 shares of Stevanato Group stock in a transaction that occurred on Monday, September 28th. The stock was sold at an average price of €21.50, for a total value of €293,453.50. Following the sale, the insider owned 400,000 shares of the company’s stock, valued at €8,600,000. The trade was a 3.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Elisabetta Magistretti sold 2,045 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of €20.09, for a total value of €41,084.05. Following the sale, the director directly owned 2,930 shares in the company, valued at €58,863.70. This trade represents a 41.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 21,926 shares of company stock valued at $459,738 in the last ninety days. Corporate insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Stevanato Group

Several large investors have recently bought and sold shares of the business. Integrated Wealth Concepts LLC purchased a new position in shares of Stevanato Group in the 2nd quarter valued at approximately $59,000. State of Wyoming purchased a new stake in Stevanato Group during the 3rd quarter worth approximately $75,000. Fifth Third Bancorp grew its position in Stevanato Group by 22.6% during the 1st quarter. Fifth Third Bancorp now owns 4,196 shares of the company’s stock worth $58,000 after purchasing an additional 773 shares during the last quarter. Hardy Reed LLC acquired a new position in Stevanato Group during the 1st quarter valued at approximately $147,000. Finally, Diversify Wealth Management LLC increased its stake in Stevanato Group by 23.9% during the 1st quarter. Diversify Wealth Management LLC now owns 18,353 shares of the company’s stock valued at $252,000 after purchasing an additional 3,543 shares in the last quarter.

Stevanato Group Company Profile

Stevanato Group S.p.A. is an Italy-based provider of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and healthcare industries. Founded in 1949, the company has developed from a glass-packaging manufacturer into an integrated supplier serving customers throughout the global pharmaceutical supply chain.

The company manufactures primary packaging products, including glass vials, syringes, cartridges and ampoules, as well as components and systems used to contain and administer injectable medicines.